Suppr超能文献

制备及新型他克莫司舌下片剂制剂的理化评价。

Preparation and physicochemical evaluation of a new tacrolimus tablet formulation for sublingual administration.

机构信息

Department of Pharmaceutical Technology and Biopharmacy, University of Groningen, Groningen, The Netherlands.

出版信息

Drug Dev Ind Pharm. 2012 Apr;38(4):490-500. doi: 10.3109/03639045.2011.613075. Epub 2011 Sep 30.

Abstract

The aim of this study was to develop a new fast-disintegrating tablet formulation containing 1 mg tacrolimus for sublingual application. First, solid dispersions containing tacrolimus (2.5%, 5% and 10% w/w) incorporated in Ac-Di-Sol(®) and carriers (inulin 1.8 kDa and 4 kDa, and polyvinylpyrrolidone (PVP) K30) were prepared by freeze drying. Subsequently, a tablet formulation composed of a mixture of the solid dispersions, Ac-Di-Sol(®), mannitol, Avicel(®) PH-101 and sodium stearyl fumarate was optimized concerning drug load in the solid dispersions and the type of carrier. Tablet weight was kept constant at 75 mg by adjusting the amount of Avicel(®) PH-101. Differential scanning calorimetry (DSC) and X-ray powder diffraction (XRPD) results indicated the absence of the drug in the crystalline state, which was confirmed by the scanning electron microscopy (SEM). These results suggest that tacrolimus incorporated in all of the solid dispersions was fully amorphous. Dissolution of the tablets containing solid dispersions with a low drug load highly depends on the type of carrier and increased in the order: PVP K30 < inulin 4 kDa < inulin 1.8 kDa. Solid dispersions with a drug load of 10% w/w incorporated in the carriers yielded optimal formulations. In addition, the physicochemical characteristics and the dissolution behavior of the tablet formulation containing inulin 1.8 kDa-based solid dispersions with a drug load of 10% w/w did not change after storage at 20°C/45%RH for 6 months indicating excellent storage stability.

摘要

本研究旨在开发一种新的 1 毫克他克莫司速崩片剂型,用于舌下给药。首先,通过冷冻干燥制备含有他克莫司(2.5%、5%和 10%w/w)的固体分散体,其包含 Ac-Di-Sol(®)和载体(菊粉 1.8kDa 和 4kDa 以及聚乙烯吡咯烷酮(PVP)K30)。随后,优化了由固体分散体混合物、Ac-Di-Sol(®)、甘露醇、Avicel(®) PH-101 和富马酸硬脂酰组成的片剂配方,以考虑固体分散体中的药物负载和载体类型。通过调整 Avicel(®) PH-101 的用量,将片剂重量保持在 75mg 不变。差示扫描量热法(DSC)和 X 射线粉末衍射(XRPD)结果表明药物不存在于结晶状态,这通过扫描电子显微镜(SEM)得到证实。这些结果表明,他克莫司完全掺入所有固体分散体中是无定形的。低药物负载的片剂中固体分散体的溶出高度依赖于载体的类型,并按以下顺序增加:PVP K30 < 菊粉 4kDa < 菊粉 1.8kDa。载有 10%w/w 药物负载的固体分散体的固体分散体产生了最佳配方。此外,在 20°C/45%RH 下储存 6 个月后,含有 10%w/w 药物负载的基于菊粉 1.8kDa 的固体分散体的片剂配方的物理化学特性和溶出行为没有变化,表明其具有优异的储存稳定性。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验